Please ensure Javascript is enabled for purposes of website accessibility

Generic Drugs Leave Rite Aid Feeling Sick

By Travis Hoium - Apr 4, 2013 at 10:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Growing sales of generic drugs have sales falling at Rite Aid.

Generic drugs are good for consumers' wallets, but they aren't good for many other players in the medical industry. Pharmaceutical companies that spend billions of dollars to develop brand name drugs feel the pinch when patents run out, and generics flood the market. Apparently, so do drug stores.

Rite Aid (RAD 9.02%) said today that same store sales fell 2% in March from a year earlier, driven by a decline in drug sales. Sales in the pharmacy, which accounts for 67.6% of overall revenue at Rite Aid, fell 4.5%, despite prescriptions rising slightly. This means that lower cost drugs, particularly in the form of generics, have taken a bite out of sales for Rite Aid.

The small silver lining is that the rest of the store is doing quite well. Front-end same-store sales, which is everything outside of the pharmacy, rose 3.8%, helped by a boost in Easter sales.

An industry trend takes hold
This is going to be a challenge for the industry going forward, and will also impact Walgreen's (WBA 1.02%) and CVS (CVS 1.08%). Walgreens reported a 0.7% rise in same-store sales for March, which was below expectations, showing similar trends as Rite Aid's. The company's same-store pharmacy sales fell 1.5%, not as bad as Rite Aid, but still not a strong sign for the drug business.  

CVS doesn't give the same-store sales data like Rite Aid and Walgreen's but we can assume the trend of more generics and lower pharmacy sales will hold true.

Investors should be careful buying into the declining sales trends at all three companies. As health-care costs have risen, there has been pressure on all parts of the industry to cut costs, and that includes drug stores. That wouldn't be a problem if the stocks were a screaming value, but Walgreen's and CVS both have P/E ratios above 18, which is expensive considering sales trends, and Rite Aid is a risky turnaround story. That's too much for this Fool to pay to get into the drug business.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
WBA
$42.51 (1.02%) $0.43
CVS Health Corporation Stock Quote
CVS Health Corporation
CVS
$97.49 (1.08%) $1.04
Rite Aid Corporation Stock Quote
Rite Aid Corporation
RAD
$5.20 (9.02%) $0.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
322%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.